Low cardiac output stimulates vasopressin release in patients with stage D heart failure – Its relevance to poor prognosis and reversal by surgical treatment –

Circulation Journal

Volumn 78, Issue 9, 2014, Pages 2259-2267

  Imamura, Teruhiko ^a   Hatano, Masaru ^a   Fujino, Takeo ^a   Inaba, Toshiro ^a   Maki, Hisataka ^a   Komuro, Issei ^a   Kinugawa, Koichiro ^a   Kyo, Shunei ^a   Kinoshita, Osamu ^a   Nawata, Kan ^a   Ono, Minoru ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Hyponatremia; Osmolality; Survival; Ventricular assist device

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ARGIPRESSIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INOTROPIC AGENT; VASOPRESSIN DERIVATIVE;

ADULT; ARTICLE; COMPARATIVE STUDY; DOPPLER ECHOGRAPHY; FEMALE; HEART EJECTION FRACTION; HEART FAILURE; HEART HEMODYNAMICS; HEART INDEX; HEART OUTPUT; HEART TRANSPLANTATION; HUMAN; HYPONATREMIA; IMPLANTATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PROGNOSIS; RADIOIMMUNOASSAY; RETROSPECTIVE STUDY; SERUM OSMOLALITY; SODIUM BLOOD LEVEL; SURVIVAL; TRANSTHORACIC ECHOCARDIOGRAPHY; VASOPRESSIN RELEASE; VENTRICULAR ASSIST DEVICE; AGED; BLOOD; CLINICAL TRIAL; COMPLICATION; ELECTROLYTE BALANCE; FORWARD HEART FAILURE; PATHOPHYSIOLOGY;

ADULT; AGED; CARDIAC OUTPUT, LOW; HEART FAILURE; HUMANS; HYPONATREMIA; MIDDLE AGED; VASOPRESSINS; WATER-ELECTROLYTE BALANCE;

EID: 84906819059     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-14-0368     Document Type: Article

References (28)

1. Robertson GL. Antidiuretic hormone: Normal and disordered function. Endocrinol Metab Clin North Am 2001; 30: 671-694.
2. Robertson GL, Mahr EA, Athar S, Sinha T. Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma. J Clin Invest 1973; 52: 2340-2352.
3. Kinugawa K, Imamura T, Komuro I. Experience of a vasopressin receptor antagonist, tolvaptan, under the unique indication in Japanese heart failure patients. Clin Pharmacol Ther 2013; 94: 449-451.
4. Schrier RW, Berl T, Anderson RJ. Osmotic and nonosmotic control of vasopressin release. Am J Physiol 1979; 236: F321-F332.
5. Goldsmith SR, Francis GS, Cowley AW Jr, Goldenberg IF, Cohn JN. Hemodynamic effects of infused arginine vasopressin in congestive heart failure. J Am Coll Cardiol 1986; 8: 779-783.
6. Lanfear DE, Sabbah HN, Goldsmith SR, Greene SJ, Ambrosy AP, Fought AJ, et al. Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: Insights from the EVEREST trial. Circ Heart Fail 2013; 6: 47-52.
7. Uretsky BF, Verbalis JG, Generalovich T, Valdes A, Reddy PS. Plasma vasopressin response to osmotic and hemodynamic stimuli in heart failure. Am J Physiol 1985; 248: H396-H402.
8. Szatalowicz VL, Arnold PE, Chaimovitz C, Bichet D, Berl T, Schrier RW. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med 1981; 305: 263-266.
9. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation1990; 82: 1724-1729.
10. Goldsmith SR, Francis GS, Cowley AW Jr. Arginine vasopressin and the renal response to water loading in congestive heart failure. Am J Cardiol 1986; 58: 295-299.
11. Nielsen S, Kwon TH, Christensen BM, Promeneur D, Frokiaer J, Marples D. Physiology and pathophysiology of renal aquaporins. J Am Soc Nephrol 1999; 10: 647-663.
12. Goldsmith SR. Vasopressin as vasopressor. Am J Med 1987; 82: 1213-1219.
13. LeJemtel TH, Serrano C. Vasopressin dysregulation: Hyponatremia, fluid retention and congestive heart failure. Int J Cardiol 2007; 120: 1-9.
14. Kinugawa K. How to treat stage D heart failure? When to implant left ventricular assist devices in the era of continuous flow pumps? Circ J 2011; 75: 2038-2045.
15. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: The Framingham study. N Engl J Med 1971; 285: 1441-1446.
16. Anderson RJ, Pluss RG, Berns AS, Jackson JT, Arnold PE, Schrier RW, et al. Mechanism of effect of hypoxia on renal water excretion. J Clin Invest 1978; 62: 769-777.
17. Creager MA, Faxon DP, Cutler SS, Kohlmann O, Ryan TJ, Gavras H. Contribution of vasopressin to vasoconstriction in patients with congestive heart failure: Comparison with the renin-angiotensin system and the sympathetic nervous system. J Am Coll Cardiol 1986; 7: 758-765.
18. Schrier RW, Berl T, Harbottle JA, McDonald KM. Catecholamines and renal water excretion. Nephron 1975; 15: 186-196.
19. Levine TB, Francis GS, Goldsmith SR, Simon AB, Cohn JN. Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. Am J Cardiol 1982; 49: 1659-1666.
20. Goldsmith SR, Francis GS, Cowley AW Jr, Levine TB, Cohn JN. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol 1983; 1: 1385-1390.
21. Goldsmith SR. Baroreflex loading maneuvers do not suppress increased plasma arginine vasopressin in patients with congestive heart failure. J Am Coll Cardiol 1992; 19: 1180-1184.
22. Rai A, Whaley-Connell A, McFarlane S, Sowers JR. Hyponatremia, arginine vasopressin dysregulation, and vasopressin receptor antagonism. Am J Nephrol 2006; 26: 579-589.
23. Tada Y, Nakamura T, Funayama H, Sugawara Y, Ako J, Ishikawa S, et al. Early development of hyponatremia implicates short- and long-term outcomes in ST-elevation acute myocardial infarction. Circ J 2011; 75: 1927-1933.
24. Rittig S, Knudsen UB, Norgaard JP, Pedersen EB, Djurhuus JC. Abnormal diurnal rhythm of plasma vasopressin and urinary output in patients with enuresis. Am J Physiol 1989; 256: F664-F671.
25. Trudel E, Bourque CW. Central clock excites vasopressin neurons by waking osmosensory afferents during late sleep. Nat Neurosci 2010; 13: 467-474.
26. Schrier RW. Role of diminished renal function in cardiovascular mortality: Marker or pathogenetic factor? J Am Coll Cardiol 2006; 47: 1-8.
27. Imamura T, Kinugawa K, Shiga T, Kato N, Muraoka H, Minatsuki S, et al. Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients: Association between non-responders and chronic kidney disease. Circ J 2013; 772: 397-404.
28. Imamura T, Kinugawa K, Minatsuki S, Muraoka H, Kato N, Inaba T, et al. Urine osmolality estimated using urine urea nitrogen, sodium and creatinine can effectively predict response to tolvaptan in decompensated heart failure patients. Circ J 2013; 775: 1208-1213.